Literature DB >> 9063913

Caffeine consumption in hospitalized psychiatric patients.

M Rihs1, C Muller, P Baumann.   

Abstract

A total of 98 consecutively admitted psychiatric inpatients were asked for their daily consumption of coffee, tea and other products containing caffeine. Calculation of the corresponding daily caffeine intake was performed using data from the literature and from caffeine measurements carried out in different coffee and tea preparations in the hospital. Of the patients 13% presented a high (> or = 750 mg daily) caffeine consumption before hospitalization. The average caffeine consumption per day decreased from 405 mg before to 332 mg during hospitalization (P < 0.04), but the before and during hospitalization caffeine consumptions were highly correlated (rho = 0.651; P < 0.00001). The decrease in caffeine consumption seems to be influenced by a lower availability of caffeine at hospital. Among the diagnostic groups (DSM-III-R criteria), the caffeine intake was highest in schizophrenia and lowest in anxiety and major depression patients. Patients under a neuroleptic treatment before admission presented a higher caffeine intake. At hospital the high caffeine users showed the highest score on the factor depression (Hopkins Symptom Checklist; HSCL-58). However, the influence of other factors, such as weight and cigarette consumption, which correlated also with the caffeine intake (rho = 0.359; P < 0.001; and rho = 0.83; P < 0.00001, respectively), have also to be considered. Our data suggest that inquiry into caffeine consumption should be included routinely for psychiatric patients, e.g. at admission, because patients with a psychotic disorder undergo a higher risk for an excessive caffeine consumption.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9063913     DOI: 10.1007/bf02274898

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  20 in total

Review 1.  A psychopharmacological and psychophysiological evaluation of smoking motives.

Authors:  R Nil
Journal:  Rev Environ Health       Date:  1991       Impact factor: 3.458

2.  Low-dose caffeine discrimination in humans.

Authors:  R R Griffiths; S M Evans; S J Heishman; K L Preston; C A Sannerud; B Wolf; P P Woodson
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

3.  Reinforcing and subjective effects of caffeine in normal human volunteers.

Authors:  K N Stern; L D Chait; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Psychotropic effects of caffeine in man. 3. A questionnaire survey of coffee drinking and its effects in a group of housewives.

Authors:  A Goldstein; S Kaizer
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

5.  Psychotropic effects of caffeine in man. II. Alertness, psychomotor coordination, and mood.

Authors:  A Goldstein; S Kaizer; R Warren
Journal:  J Pharmacol Exp Ther       Date:  1965-10       Impact factor: 4.030

Review 6.  Physiologic and psychotropic effects of caffeine on man. A review.

Authors:  P E Stephenson
Journal:  J Am Diet Assoc       Date:  1977-09

7.  The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects.

Authors:  M Bruce; N Scott; M Lader; V Marks
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

8.  Anxiety and depression associated with caffeinism among psychiatric inpatients.

Authors:  J F Greden; P Fontaine; M Lubetsky; K Chamberlin
Journal:  Am J Psychiatry       Date:  1978-08       Impact factor: 18.112

9.  Treatment of alcoholism and concomitant drugs of abuse.

Authors:  A R Zeiner; T Stanitis; M Spurgeon; N Nichols
Journal:  Alcohol       Date:  1985 May-Jun       Impact factor: 2.405

10.  Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence.

Authors:  J P Boulenger; T W Uhde; E A Wolff; R M Post
Journal:  Arch Gen Psychiatry       Date:  1984-11
View more
  15 in total

Review 1.  Caffeine Use Disorder: A Comprehensive Review and Research Agenda.

Authors:  Steven E Meredith; Laura M Juliano; John R Hughes; Roland R Griffiths
Journal:  J Caffeine Res       Date:  2013-09

2.  Smoking among individuals with schizophrenia in Korea: gender differences.

Authors:  Sun S Kim; Sangkeun Chung; Jong-Il Park; Ae-Ja Jung; David Kalman; Douglas M Ziedonis
Journal:  Arch Psychiatr Nurs       Date:  2013-07-26       Impact factor: 2.218

3.  Higher serum caffeine in smokers with schizophrenia compared to smoking controls.

Authors:  Kunal K Gandhi; Jill M Williams; Matthew Menza; Magdalena Galazyn; Neal L Benowitz
Journal:  Drug Alcohol Depend       Date:  2010-03-12       Impact factor: 4.492

Review 4.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  Activation of elements in HERV-W family by caffeine and aspirin.

Authors:  Chunlan Liu; Yatang Chen; Shan Li; Honglian Yu; Jie Zeng; Xiuling Wang; Fan Zhu
Journal:  Virus Genes       Date:  2013-06-28       Impact factor: 2.332

6.  Caffeine intake from all sources in adolescents and young adults in Austria.

Authors:  E Rudolph; A Faerbinger; J Koenig
Journal:  Eur J Clin Nutr       Date:  2014-04-02       Impact factor: 4.016

7.  Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.

Authors:  Amy B Adolfo; Christopher G AhnAllen; Jennifer W Tidey
Journal:  Schizophr Res       Date:  2008-11-08       Impact factor: 4.939

8.  Associations of Coffee, Diet Drinks, and Non-Nutritive Sweetener Use with Depression among Populations in Eastern Canada.

Authors:  Zhijie M Yu; Louise Parker; Trevor J B Dummer
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 9.  Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.

Authors:  Laura López-Cruz; John D Salamone; Mercè Correa
Journal:  Front Pharmacol       Date:  2018-06-01       Impact factor: 5.810

10.  Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice.

Authors:  Aleksandra Szopa; Ewa Poleszak; Elżbieta Wyska; Anna Serefko; Sylwia Wośko; Aleksandra Wlaź; Mateusz Pieróg; Andrzej Wróbel; Piotr Wlaź
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-27       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.